/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/supportive-care/,

/clinical/cckm-tools/content/beacon-protocols/supportive-care/name-122922-en.cckm

201711331

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Supportive Care

CSC SC Darbepoetin Monthly Ver 11-20-17 (HL 1849)

CSC SC Darbepoetin Monthly Ver 11-20-17 (HL 1849) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Supportive Care


CSC SC DARBEPOETIN MONTHLY VER: 11-20-17 –  Properties
Cycle 1 –  11/21/2017 through 12/18/2017 (28 days), Planned
Day 1, Cycle 1 –  Planned for 11/21/2017
Pre-Labs
TRANSFERRIN
Expires: S+365
FERRITIN
Expires: S+365
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 2 –  12/19/2017 through 1/15/2018 (28 days), Planned
Day 1, Cycle 2 –  Planned for 12/19/2017
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 3 –  1/16/2018 through 2/12/2018 (28 days), Planned
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:13:10 AM Page 1 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

Day 1, Cycle 3 –  Planned for 1/16/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 4 –  2/13/2018 through 3/12/2018 (28 days), Planned
Day 1, Cycle 4 –  Planned for 2/13/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 5 –  3/13/2018 through 4/9/2018 (28 days), Planned
Day 1, Cycle 5 –  Planned for 3/13/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:13:10 AM Page 2 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 6 –  4/10/2018 through 5/7/2018 (28 days), Planned
Day 1, Cycle 6 –  Planned for 4/10/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:13:10 AM Page 3 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org